<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01689805</url>
  </required_header>
  <id_info>
    <org_study_id>FLG-255-AR</org_study_id>
    <nct_id>NCT01689805</nct_id>
  </id_info>
  <brief_title>Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis</brief_title>
  <official_title>Do Mutations in the Filaggrin Gene Have Clinical Importance for the Treatment Outcome in Atopic Dermatitis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <authority>Finland: Ministry of Social Affairs and Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a common disease which affects about one million people in Finland at
      some stage of their life. In atopic dermatitis we see a superficial inflammation of the skin
      and a defect in skin barrier function. The filaggrin protein plays a central role in the
      skin barrier function and studies indicate that about 30% of patients with atopic dermatitis
      have a mutation in the filaggrin gene. The aim of the study is to investigate whether a
      mutation in the filaggrin gene affects the clinical treatment outcome in patients with
      atopic dermatitis. If a mutation predisposes to a worse response to treatment, this could be
      examined and those patients with the mutation could be given extra treatment support for
      their atopic dermatitis. The prevalence of filaggrin mutation in the Finnish non-atopic
      population is studied in the control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Filaggrin mutation</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgE</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Patients with atopic dermatitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-atopic controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples are collected to investigate if the patient has a mutation in the filaggrin
      gene.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atopic dermatitis who are followed-up at the Skin and Allergy Hospital in
        Helsinki for at least one year can be included in the study.

        The control population consists of non-atopic persons without any other skin disease
        (samples for the control population are applied for from a sample collection of the
        National institute for health and welfare).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (patients with atopic dermatitis):

          -  Age at least 18 years

          -  Clinical diagnosis of atopic dermatitis

          -  Need for follow-up at the Skin and Allergy Hospital

          -  Patient gives signed informed consent to participate in this study

          -  Patients parents and grandparents are of Finnish origin

        Inclusion Criteria (Controls):

          -  No history of atopy or skin disease

          -  Age at least 18 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Remitz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin and Allergy Hospital, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anita Remitz, MD, PhD</last_name>
    <phone>+358-9-4711</phone>
    <email>anita.remitz@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin and Allergy Hospital, Departments of Dermatology and Clinical Genetics</name>
      <address>
        <city>Helsinki</city>
        <zip>PB 160</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Remitz, MD, PhD</last_name>
      <email>anita.remitz@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Anita Remitz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sakari Reitamo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna M Mandelin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ville Kiiski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minna Pöyhönen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eveliina Salminen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sirpa Kivirikko, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 18, 2012</lastchanged_date>
  <firstreceived_date>June 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Anita Remitz</investigator_full_name>
    <investigator_title>MD, PhD, Specialist in Dermatology</investigator_title>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Filaggrin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
